All stock lists
ADMA Biologics Inc (NASDAQ:ADMA)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
13.18+2.69 (+25.72%)
Market cap
$2.95B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 17, 2013
Website
Insider Score
––Not scored
ADMA Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
ADMA analyst forecast
ADMA analyst consensus
Hold1 ratings
Buy 0 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ADMA 12-month price target
$18.00+34.9% upsideaverage of 1 firm
$18.00High
$18.00Low
ADMA ratings mix, last 12 months
Buy Hold Sell
Best analysts covering ADMA
- Mizuho100%success rate · +105.6% avg return · 6 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ADMA analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Cantor Fitzgerald | Neutral | — | — | Reiterated | 2026-11-05 |
| Mizuho Securities | — | $18.00 | +71.8% | — | 2026-11-05 | |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-15 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-05-07 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-05-07 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-04-13 |
| — | Cantor Fitzgerald | Neutral | — | — | Downgraded | 2026-03-26 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2025-05-08 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-03-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-08 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2024-11-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-14 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-09 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-07-09 |
| — | Mizuho | Buy | — | — | Reiterated | 2024-06-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-10 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2024-05-10 |
| — | Mizuho | Buy | — | — | Reiterated | 2024-05-10 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-05-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-26 |
| — | Mizuho | Buy | — | — | Reiterated | 2024-03-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-02-29 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-02-29 |
| — | Mizuho | Buy | — | — | Reiterated | 2024-01-22 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-01-09 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-12-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-11-17 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-08-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-10 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2023-08-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-03-27 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-02-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-01-03 |
| — | Mizuho | Buy | — | — | Reiterated | 2022-11-10 |
| — | Mizuho | Buy | — | — | Reiterated | 2022-10-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-07-25 |
| — | Raymond James | Strong Buy | — | — | Upgraded | 2021-11-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2021-11-09 |
| — | Raymond James | Outperform | — | — | Reiterated | 2021-10-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-08-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-07-06 |
| — | Raymond James | Outperform | — | — | Reiterated | 2021-03-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-01-04 |
| — | Raymond James | Outperform | — | — | Reiterated | 2020-10-01 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2020-05-07 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2020-03-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-03-16 |
| — | Jefferies | Buy | — | — | Reiterated | 2019-06-04 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2019-04-02 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2018-10-30 |
| — | Raymond James | Outperform | — | — | Reiterated | 2018-10-12 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2018-07-30 |
| — | Maxim Group | Buy | — | — | Reiterated | 2018-07-27 |
| — | Maxim Group | Buy | — | — | Upgraded | 2018-07-26 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2018-07-13 |
| — | Raymond James | Outperform | — | — | Upgraded | 2017-11-14 |
| — | Raymond James | Market Perform | — | — | Downgraded | 2016-08-01 |
| — | Maxim Group | Hold | — | — | Downgraded | 2016-08-01 |
ADMA earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-25 | 0.18 | 0.20 | $139.6M | $139.2M |
| 2026-05-06 | 0.19 | 0.19 | $140.0M | $114.5M |
| 2026-08-05 | 0.16 | 0.16 | $125.3M | $124.4M |
| 2026-11-04 | 0.20 | 0.23 | $138.1M | $141.1M |
| 2027-02-24Upcoming | 0.22 | — | $158.4M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.